miltefosine + meglumine antimoniate

Miltefosine + meglumine antimoniate is a combination therapeutic regimen primarily investigated for the treatment of various forms of leishmaniasis, including cutaneous and visceral leishmaniasis. Miltefosine is an oral alkylphosphocholine that acts by interfering with parasite cell signaling, specifically inhibiting protein kinase C and inducing apoptosis-like cell death. Meglumine antimoniate is a pentavalent antimonial administered parenterally (intramuscularly or intralesionally) that inhibits parasite energy metabolism by targeting trypanothione reductase and glycolytic enzymes. The combination is designed to improve clinical cure rates, shorten treatment duration, and reduce the cumulative toxicity associated with antimonial monotherapy. This regimen has been evaluated in several Phase 2 and Phase 3 clinical trials, particularly in endemic regions of South America and South Asia, often supported by organizations like the Drugs for Neglected Diseases initiative (DNDi).

Other names

miltefosine and meglumine antimoniate combination therapy